Infliximab avoiding colectomy and maintaining remission in pediatric immunosuppressive-naive ulcerative colitis achieving remarkable mucosal healing

Panminerva Medica

Volumn 52, Issue 1, 2010, Pages 91-92

  Sciaudone, G ^a   Pellino, G ^a   Guadagni, I ^a   Selvaggi, F ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b EBSQ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

CASE REPORT; CHILD; COLON; FEMALE; HUMAN; IMMUNOLOGY; LETTER; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; CHILD; COLITIS, ULCERATIVE; COLON; FEMALE; GASTROINTESTINAL AGENTS; HUMANS;

EID: 77954697916     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Travis SPL, Stange EF, Ldmann M, 0resland T, Bemelman WA, Chowers Y et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis 2008;2:24-62.
2. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476 (Pubitemid 41770166)
3. Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis 2008;40:S260-4.
4. Daperno M, Sostegni R, Pera A, Rognone D, Rigazio C, Ercole E et al. The role of endoscopic assessment in ulcerative colitis in the era of infliximab. Dig Liver Dis. 2008;40:S220-4.
5. Van Assche G, Vermeire S, Rutgeerts P. Immunosuppression in inflammatory bowel disease: traditional, biological or both? Curr Opin Gastroenterol 2009;25:323-328